Veracyte, Inc. announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July 12-15 in San Francisco.
The findings are derived from Veracyte’s Afirma GRID (Genomic Resource for Intelligent Discovery) database and research tool and provide new insights into the molecular drivers and complexity of thyroid cancer.
The following posters will be presented in the ENDOExpo Poster Area of the Moscone Convention Center:
Title: Vitamin D Signaling Expression Markers in Thyroid Tumors
Presenter: Ryan Conard, M.D., University of Colorado School of Medicine
Poster #: MON-379
Date/Time: Monday, July 14, from 12:00-1:30 p.m. PT
Title: Development of a Prognostic Cell Cycle Progression Score in Preoperative Thyroid Tumor Samples to Predict Prognosis
Presenter: Athanasios Bikas, M.D., Ph.D., Brigham and Women’s Hospital
Poster #: MON-380
Date/Time: Monday, July 14, from 12:00-1:30 p.m. PT
Title: Retinoic Acid Receptor (RAR) and Retinoid X Receptor (RXR) Expression in Preoperative Thyroid Tumor Samples
Presenter: Joanne Lin, M.D.,University of Colorado School of Medicine
Poster #: MON-392
Date/Time: Monday, July 14, from 12:00-1:30 p.m. PT
